New drug found to reduce exacerbations in uncontrolled asthma

New drug found to reduce exacerbations in uncontrolled asthma

London, Sep 6 (IANS) A new asthma drug currently in development has been found to reduce exacerbations in severe, uncontrolled asthma in two advanced trials involving more than 2,500 patients.

A year’s course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations — cutting the rate of exacerbations by a third to a half compared with placebo among people with the most severe form of asthma, the findings showed.

The two trials, published in the journal The Lancet, looked at the safety and efficacy of benralizumab as an add-on therapy for patients with severe, uncontrolled asthma — a group of patients who have few treatment options available and high rates of hospitalisation.

“Additional therapeutic options to control severe asthma are urgently needed and our findings support the use of benralizumab as an add-on therapy for the treatment of severe asthma with persistent eosinophilia,” said one of the researchers J. Mark FitzGerald from University of British Columbia, Vancouver, Canada.

Eosinophils are a type of white blood cell and part of the immune system controlling the mechanism associated with allergy and asthma.

Many patients with severe, uncontrolled asthma have high levels of eosinophils in the blood and airways (known as eosinophilia) which is associated with frequent asthma exacerbations, high symptom burden and impaired lung function.

Cytokine interleukin-5 (IL-5) is the main driver of eosinophil proliferation, maturation, activation and survival.

Two currently available drugs, mepolizumab and reslizumab, target the IL-5 molecule itself to stop the process of eosinophil maturation.

Benralizumab, on the other hand, uses a different pathway by targeting the IL-5 receptor, causing eosinophil apoptosis (cell death).

“The results from both trials indicate that benralizumab treatment once every four or eight weeks decreased eosinophil counts, reduced asthma exacerbations, and improved lung function for patients with severe, uncontrolled asthma with eosinophilia” FitzGerald noted.

The drug could be available to patients by the end of next year, The Telegraph reported on Monday.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of or any employee thereof. is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here